Quality Management (QMS)

Our laboratory in Frankfurt am Main, Germany, has established and implemented a Quality Management System (QMS) according to ISO9001 since 2009.

This QMS allows us to provide our clients with products and services that are generated and executed under controlled conditions. Furthermore, this demonstrates the high quality standards that are applied within our biomarker services business and the dependability of results that are generated by our proteomics technologies.

Case studies

Turning problems into solutions

Profiling New Drug Targets for Alzheimer’s Disease

Goal – Identify key regulatory pathways and proteins that mediate damage related to hyper-phosphorylated tau in human brain tissue. Outcome –…

Stacking the Odds in Alzheimer’s Disease Drug Development

Goal – Establish the mechanism of action of two orally available, brain-penetrant small molecule inhibitors of casein kinase 1 delta that improved cognition…

Unravelling the Mechanism of Action of Combined Targets in Melanoma

Goal – Analyse the context in which melanoma-derived cell lines exploit MEK and PI3K signalling to overcome BRAF V600E resistance. Outcome – Identification…

Translating Experimental Model Data to Human Disease

Goal – Establish common mechanisms of actions between preclinical mice treated with CK1D inhibitors and post mortem human AD brain tissue. Outcome – With…

The Hunt for Early Diagnostic Biomarkers of AD

Goal – Profile protein markers of neuroinflammation in AD cerebrospinal fluid. Outcome – Identification of 41 proteins with at least 60% regulation in AD…

Clusterin Glycosylation – A Prognostic AD Plasma Biomarker

Goal – Characterize plasma clusterin glycosylation associated with increasing brain atrophy. Outcome – Eight β64N clusterin glycoforms were associated…

Our Proteomic Services are fully audited for your pre-clinical and clinical study needs

learn more